Effect of Oxytocin on Stress in Marijuana Users

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate how people who frequently use marijuana respond to a stressful task, and if a medication (oxytocin) affects this response.

Clinical Trial Description

Stress is commonly associated with drug craving and relapse in substance-dependent individuals. Several studies indicate that hypothalamic neuropeptides may mediate behavioral response to stress. For example, preclinical and clinical investigations have indicated that the neuropeptide oxytocin exerts anxiolytic effects in stress paradigms. Several studies have indicated that oxytocin promotes trust, social bonding, and calmness; however, little is known about the potential anxiolytic affects of oxytocin in marijuana-dependent individuals. A preclinical study investigating the effects and mechanism of lithium on cannabinoid withdrawal in rats had positive findings, with increasing oxytocin levels hypothesized to moderate this effect (Cui et al, 2001). Given the anxiolytic nature of oxytocin, it may have a therapeutic role in ameliorating the negative affect commonly observed prior to relapse in marijuana-dependent individuals, as well as the anxiety associated with marijuana withdrawal. This pilot protocol will provide important preliminary data on the effect of oxytocin on stress in marijuana-dependent individuals. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01335789
Study type	Interventional
Source	Medical University of South Carolina
Contact
Status	Completed
Phase	N/A
Start date	March 2011
Completion date	July 2012

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT00875836` - Buspirone Treatment for Marijuana Dependence	Phase 4
Completed	`NCT00893269` - The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep	Phase 1
Completed	`NCT00490269` - Ph1 Marinol Interaction Study - Part 2 - 1	Phase 1
Completed	`NCT02579421` - Hormones and Reduction in Co-users of Marijuana and Nicotine	N/A
Terminated	`NCT01598896` - Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia	Phase 2/Phase 3
Completed	`NCT00373295` - Effect of Baclofen on Marijuana Withdrawal and Relapse	Phase 2
Active, not recruiting	`NCT01827332` - Effect of Oxytocin on Craving and Therapy Response	N/A
Terminated	`NCT00438139` - Ph1 Marinol Interaction Study - Part 1 - 1	Phase 1
Completed	`NCT02955329` - Vaping THC From Electronic Cigarettes	Phase 3
Completed	`NCT02439814` - Pregnenolone and Marijuana Dependence	Phase 2
Completed	`NCT01039415` - Attempts to Stop/Reduce Marijuana Among Dependent Users	N/A
Completed	`NCT01347762` - Nabilone for Cannabis Dependence: A Pilot Study	Phase 2/Phase 3
Completed	`NCT00270803` - The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana	N/A
Completed	`NCT01020019` - Combined Pharmacotherapy for Cannabis Dependency	Phase 2/Phase 3
Completed	`NCT02030665` - Marijuana Treatment Project 4	N/A
Completed	`NCT00107588` - Marijuana Treatment Project - 3	N/A
Completed	`NCT02011516` - Baclofen Effects on Marijuana Dependence	Phase 2
Recruiting	`NCT00598052` - Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy	N/A
Completed	`NCT00374127` - Comparison Between Marijuana Smoked in Cigarette Paper Versus Cigar Paper	Phase 2
Completed	`NCT00350649` - Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management	Phase 2